📰 GeneralCNBCFriday, October 30, 2026 at 6:00 AM UTC1h ago

A pharma giant is moving past one patent cliff — but another is already looming

Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks

Read full article at CNBC →

Originally published by CNBC. Summary and curation by DutyStation News.

← Back to News

A pharma giant is moving past one patent cliff — but another is already looming

📰 Related Stories

BOJ holds rates as underlying inflation aligns with 2% target for first time since 2013

Binance Grapples With ‘Security Incident’ That May Cause $6.3 Billion in Losses

You don’t need to believe in a god to get a religious exemption from using AI at work

Intel plunges on a major guidance miss. What went wrong — and how to proceed

Microsoft plans to raise $25 billion in debt as it pursues AI buildout

The director of Obsession put a new horror short on YouTube